Dr. Konecny on the Indications for PARP Inhibitors in Recurrent Ovarian Cancer
Gottfried E. Konecny, MD
Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses the indications for the FDA-approved PARP inhibitors in recurrent ovarian cancer.
There are currently 3 FDA-approved PARP inhibitors in this setting, Konecny says. Olaparib (Lynparza) is approved for the treatment of patients who have had 3 prior lines of chemotherapy and as maintenance therapy for patients in a complete response (CR) or partial response (PR) to platinum-based chemotherapy. Similarly, rucaparib (Rubraca) is approved for the treatment of patients who have had at least 2 prior lines of chemotherapy or as maintenance therapy in patients who have had a CR or PR to chemotherapy. Next, niraparib (Zejula) is also indicated as maintenance therapy in patients who have had a CR or PR to platinum-based chemotherapy.
Konecny concludes that the field has 3 approved drugs for broad use in recurrent ovarian cancer, either as maintenance therapy in platinum-sensitive patients or as treatment for patients with a germline or somatic BRCA mutation and deficiency in homologous recombination.